Tempus AI, Inc. (TEM)
Tempus AI uses massive datasets and artificial intelligence to help doctors personalise cancer treatments and speed up medical research.
Is Tempus AI, Inc. a good stock for a UK beginner?
The honest version: There's no rating here and nothing for sale. In its favour: Strong revenue growth of over 36%. Worth weighing: Currently losing money on a net basis. Below, we lay out what it does, what its numbers mean, and the honest risks, so you can decide for yourself.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
How much has Tempus AI, Inc. actually fallen?
Over the last 2 years of daily prices, Tempus AI, Inc. fell as much as −60% from a high to a later low. Drops of this size are a normal part of owning a share - worth knowing in advance, so a dip doesn't come as a shock.
Worst peak-to-trough fall in the daily closing price over the period we hold. Past falls are not a forecast - it can fall further, or recover.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Tempus becomes an essential standard for data-driven medicine globally.
Failure to differentiate from larger tech rivals or regulatory hurdles.
What does Tempus AI, Inc. do?
Tempus AI acts like a high-tech librarian for healthcare, gathering vast amounts of clinical and genetic data to help doctors choose the best treatments for individual patients. Revenue comes from selling pharmaceutical companies and hospitals access to this data and their analytical tools. Whether they can convert rapid growth into actual profit is the real question, since they currently spend more than they earn.
On our factor screen it looks strongest on growth and value, and weakest on momentum.
- !Pays no dividend - the whole return rides on the share price
- ✓Growing - revenue up about 22% over the year
- !Carries a lot of debt - roughly 3.2x its equity
- Growth screens high (77/100)
- Strong revenue growth of over 36%
- High gross margins suggest a scalable product
- Operates in the high-potential intersection of AI and healthcare
- Quality screens low (22/100)
- Momentum screens low (8/100)
- Income screens low (16/100)
- High volatility makes it a bumpy ride for investors
- Heavy reliance on the evolving regulatory landscape for AI in medicine
What do Tempus AI, Inc.'s numbers mean?
How much money does Tempus AI, Inc. make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Tempus AI, Inc. pay a dividend?
No - Tempus AI, Inc. doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Tempus AI, Inc. report earnings, and how did recent quarters go?
Tempus AI, Inc. is next scheduled to report on about 2026-11-03 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-07-30 | $-0.15 | $-0.04 | Beat +74% |
| 2026-05-05 | $-0.20 | $-0.13 | Beat +35% |
| 2026-02-24 | $-0.05 | $-0.04 | Beat +22% |
| 2025-11-04 | $-0.18 | $-0.11 | Beat +37% |
| 2025-08-08 | $-0.25 | $-0.22 | Beat +13% |
| 2025-05-06 | $-0.27 | $-0.24 | Beat +10% |
Across the last 6 quarters here, Tempus AI, Inc. came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Tempus AI, Inc.?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Tempus AI, Inc.?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong revenue growth: How fast the company's sales grew versus a year ago. of over 36%
- High gross margins suggest a scalable product
- Operates in the high-potential intersection of AI and healthcare
- Currently losing money on a net basis
- Very high price-to-book: The share price versus the company's net assets per share (its book value). Under 1 can look cheap, though it varies a lot by industry. ratio suggests a premium valuation
- No dividend payments for investors
- High volatility makes it a bumpy ride for investors
- Heavy reliance on the evolving regulatory landscape for AI in medicine
- Risk of burning through cash reserves before reaching profitability
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained shift to positive net income
- A significant drop in revenue growth rates
- Major changes in data privacy laws that restrict their business model
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-02 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.